{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:06:57Z","timestamp":1761523617215},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Surgical Oncology (EJSO)"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1016\/j.ejso.2009.12.002","type":"journal-article","created":{"date-parts":[[2009,12,30]],"date-time":"2009-12-30T09:22:32Z","timestamp":1262164952000},"page":"244-250","source":"Crossref","is-referenced-by-count":44,"title":["A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer"],"prefix":"10.1016","volume":"36","author":[{"given":"V.","family":"Velenik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Ocvirk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Oblak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Anderluh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ejso.2009.12.002_bib1","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1056\/NEJMoa010580","article-title":"Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer","volume":"345","author":"Kapiteijn","year":"2001","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ejso.2009.12.002_bib2","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jama.284.8.1008","article-title":"Preoperative radiotherapy for resectable rectal cancer: a meta-analysis","volume":"284","author":"Camma","year":"2000","journal-title":"JAMA"},{"issue":"9290","key":"10.1016\/j.ejso.2009.12.002_bib3","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/S0140-6736(01)06409-1","article-title":"Adjuvant radiotherapy for rectal cancer: a systematic overview of 8507 patients from 22 randomised trials","volume":"358","year":"2001","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ejso.2009.12.002_bib4","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1056\/NEJM199408253310803","article-title":"Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery","volume":"331","author":"O'Connell","year":"1994","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.ejso.2009.12.002_bib5","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1056\/NEJMoa040694","article-title":"Preoperative versus postoperative chemoradiotherapy for rectal cancer","volume":"351","author":"Sauer","year":"2004","journal-title":"N Engl J Med"},{"issue":"28","key":"10.1016\/j.ejso.2009.12.002_bib6","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.1200\/JCO.2006.06.7629","article-title":"Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203","volume":"24","author":"Gerard","year":"2006","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejso.2009.12.002_bib7","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa060829","article-title":"Chemotherapy with preoperative radiotherapy in rectal cancer","volume":"355","author":"Bosset","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejso.2009.12.002_bib8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.radonc.2003.12.006","article-title":"Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy","volume":"72","author":"Bujko","year":"2004","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2009.12.002_bib9","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s002800050043","article-title":"Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients","volume":"45","author":"Schuller","year":"2000","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1016\/j.ejso.2009.12.002_bib10","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1040-8428(00)00059-7","article-title":"Capecitabine, a new oral fluoropyrimidine for the treatment of colorectal cancer","volume":"35","author":"Di Costanzo","year":"2000","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10","key":"10.1016\/j.ejso.2009.12.002_bib11","first-page":"2948","article-title":"X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts","volume":"5","author":"Sawada","year":"1999","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ejso.2009.12.002_bib12","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ijrobp.2005.02.046","article-title":"Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancer","volume":"63","author":"Kim","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.ejso.2009.12.002_bib13","first-page":"693","article-title":"Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial","volume":"47","author":"Velenik","year":"2006","journal-title":"Croat Med J"},{"issue":"4","key":"10.1016\/j.ejso.2009.12.002_bib14","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ccr.2005.03.003","article-title":"Structural basis for inhibition of the epidermal growth factor receptor by cetuximab","volume":"7","author":"Li","year":"2005","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.ejso.2009.12.002_bib15","first-page":"1311","article-title":"Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model","volume":"1","author":"Goldstein","year":"1995","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.ejso.2009.12.002_bib16","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"Van Cutsem","year":"2009","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejso.2009.12.002_bib17","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1200\/JCO.2008.20.8397","article-title":"Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer","volume":"27","author":"Bokemeyer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2009.12.002_bib18","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejso.2009.12.002_bib19","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.ijrobp.2006.01.013","article-title":"Epidermal growth factor receptor as a prognostic factor in locally advanced rectal-cancer patients treated with preoperative chemoradiation","volume":"65","author":"Li","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.ejso.2009.12.002_bib20","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.ijrobp.2007.02.018","article-title":"Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy","volume":"68","author":"Bertolini","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.ejso.2009.12.002_bib21","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ijrobp.2008.04.065","article-title":"Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer","volume":"73","author":"Bertolini","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.ejso.2009.12.002_bib22","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/annonc\/mdl460","article-title":"Phase I\/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer","volume":"18","author":"Machiels","year":"2007","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2009.12.002_bib23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s003840050072","article-title":"Pathological features of rectal cancer after preoperative radiochemotherapy","volume":"12","author":"Dworak","year":"1997","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.ejso.2009.12.002_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2008.10.014","article-title":"Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a phase II MARGIT trial","author":"Horisberger","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"19","key":"10.1016\/j.ejso.2009.12.002_bib25","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1200\/JCO.2002.02.049","article-title":"Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer","volume":"20","author":"Dunst","year":"2002","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2009.12.002_bib26","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/sj.bjc.6603645","article-title":"A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer","volume":"96","author":"Willeke","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejso.2009.12.002_bib27","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/annonc\/mdn719","article-title":"Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: a phase II study","volume":"20","author":"Carlomagno","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2009.12.002_bib28","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1148\/radiol.2431051825","article-title":"Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the mercury study","volume":"243","year":"2007","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.ejso.2009.12.002_bib29","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/annonc\/mdn647","article-title":"Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer","volume":"20","author":"Bengala","year":"2009","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.ejso.2009.12.002_bib30","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1200\/JCO.2008.18.5033","article-title":"Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer","volume":"27","author":"Debucquoy","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Surgical Oncology (EJSO)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798309005435?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798309005435?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T07:21:24Z","timestamp":1544772084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798309005435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S0748798309005435"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2009.12.002","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}